Press Releases June 3, 2026 08:30 AM

Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Lantheus to Participate in Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
LNTH

Lantheus Holdings, a radiopharmaceutical company, announced that John Wiggins, VP of External Manufacturing, will participate in a fireside chat at the upcoming Goldman Sachs 47th Annual Global Healthcare Conference. The event will be webcast live and available for replay, providing investor insights into the company.

Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
LNTH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lantheus is a leading radiopharmaceutical company focused on improving patient outcomes through disease detection and treatment.
  • The company will feature representation at a major healthcare investor conference, signaling transparency and engagement with investors.
  • Lantheus has a global presence with offices in North America and Europe and a 70-year history in radiopharmaceuticals.

BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 9.

To access the live webcast of the presentations, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentation.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

Contacts:

Mark Kinarney
Vice President, Investor Relations
978-671-8842
[email protected]

Melissa Downs
Executive Director, External Communications
646-975-2533
[email protected]


Risks

  • Performance and growth projections may depend on the highly regulated healthcare and pharmaceutical sectors.
  • Market reaction could be influenced by the content and investor reception of the presentation, which remains uncertain until delivered.
  • External manufacturing and supply chain dynamics could impact operational effectiveness.

More from Press Releases

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Jun 6, 2026 All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026